BEYOND SYMPTOM CONTROL
Developing therapies to restore functioning in patients with orphan conditions of the brain and nervous system, so that they can live their lives to the fullest
Who We Are
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system.
Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. We will achieve our goal through a full partnership with the communities of patients, their families and caregivers and through collaboration with health care providers and policy makers.
Noema focuses on orphan CNS diseases characterized by imblanced neuronal networks leading to unresolved severe symptoms and significant impact on patient’s overall functioning.
NOE-101 mGluR5 NAM
A highly selective, potent, and cell penetrant negative allosteric modulator of mGlu5 receptors for the treatment of seizures associated with tuberous sclerosis complex (TSC) and for the management of pain associated with Trigeminal Neuralgia (TN).
NOE-105 PDE10A inhibitor
A potent selective PDE10A inhibitor that safely modulates dopamine D2 receptor signaling in people with Tourette Syndrome (TS).
Experience and Vision
The Noema team has extensive experience in global pharma and biotech organizations in developing and commercializing innovative therapies for neurological and psychiatric indications.
Chief Executive Officer
George Garibaldi, MD
Chief Medical Officer
John Kemp, PhD
Chief Scientific Officer
The Noema team successfully raised a 54 million Swiss Franc (USD59 million/EUR50 million) Series A financing round co-led by Sofinnova Partners and Polaris Partners. Sofinnova had previously provided EUR3.5 million in seed financing.